TX-SCHUMACHER-ELECTRIC
20.4.2022 15:03:06 CEST | Business Wire | Press release
Schumacher Electric Corporation , a global leader in the design, manufacture and distribution of power conversion products, today announced Lincolnshire Management, Inc. , a private equity firm focused on investing in and acquiring growing middle market companies, has completed the sale of Schumacher Electric to private investment firm Ripple Industries LLC. Financial terms of the transaction were not disclosed. The announcement was made via a live stream all-employee meeting where Mickey Leech, CEO of Schumacher Electric, also, reflected on major company milestones.
“Schumacher Electric is celebrating 75 years of power innovation. Major milestones provide us with the opportunity to pause, reflect and appreciate our past,” said Leech. “Much has changed since 1947, from our products and technologies to our people and processes. Schumacher was born out of a family legacy focused on power, performance, and innovation. The last few years have been marked by unprecedented challenges that have impacted everyone – from the professional to personal – on many levels. And yet, despite these challenges, the Schumacher team has continually risen to the occasion.”
Leech went on to review some of Schumacher’s most recent accomplishments:
- The global launch of a new line of Rugged™ Lithium Jump Starters
- The launch of the new Ultracap Battery Charger and Engine Starter
- The addition of Level 2 EV Wall Chargers to the global Schumacher EV Series™ debuting in June
- Meaningful growth in the e-commerce space across a range of marketplace and retail platforms
- The availability of Schumacher products across a wide breadth of channels that represent more than 60,000 brick-and-mortar distribution points from the leading big box to home improvement, specialty and hardware locations
“Even with these amazing accomplishments, we want to take this time to continue to re-imagine our future and what we want Schumacher Electric to look like in the next five, ten, 25 years and beyond,” said Leech. “Lincolnshire was instrumental in helping formulate the strategies that drove our successful high growth initiatives including our EV Series™ and e-commerce; now our leadership team is ready to lean in with Ripple Industries and continue that trajectory.”
William Bishop of Ripple Industries noted, “The Schumacher brand is synonymous with innovation and enhancing battery life; we share management’s vision of the big opportunities ahead as global transportation needs evolve and put greater demands on holistic power conversion solutions including battery maintenance and charging. We will move aggressively with Mickey and the entire Schumacher team to capitalize on these exciting growth opportunities.”
About Schumacher Electric Corporation
Schumacher Electric Corporation is known for industry-leading patented technologies, an unwavering commitment to quality, and providing feature-rich products that represent a remarkable value and price. Since 1947 Schumacher has been powering lifestyles with a legacy centered on delivering product excellence and exceptional service to a broad range of customer needs and experience levels. Celebrating 75 years of power conversion innovation - put your trust in a Schumacher.
To learn more visit: www.schumacherelectric.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220420005286/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom